Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated May 27, 2022, we enclose copies of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2022 published on May 28, 2022 in MINT (English) and HINDUSTAN (Hindi). We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Cooperative Agreement Of US$149.6 Million With US Government For Expansion Of Critical Vaccine Manufacturing Capacity By Jubilant Hollisterstier LLC, USA, A Wholly-Owned Subsidiary Of The Company
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to the cooperative agreement of US$149.6 Million with US Government for expansion of critical vaccine manufacturing capacity by Jubilant HollisterStier LLC, USA, a wholly-owned subsidiary of the Company. We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that audio recording of Analyst and Investor Conference Call for Audited financial results for the quarter and financial year ended March 31, 2022 held on Friday, May 27, 2022, has been uploaded on the Company''s website. The link to access the audio call recording is: https://www.jubilantpharmova.com/investors/financials/quarterly-results This is for your information and records. Jubilant Pharmova Ltd - 530019 - Board Meeting Outcome - Dividend
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on May 27, 2022, recommended a dividend of Rs. 5 (Rupees Five only) per equity share of Re. 1 each for the year ended March 31, 2022. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid/ despatched on or before September 7, 2022. We request you to take the same on record. Q4FY22 Quarterly Result Announced for Jubilant Pharmova Ltd.
Jubilant Pharmova announced Q4FY22 results: Q4FY22: Revenue was at Rs 1,528 Crore versus Rs 1,580 Crore in Q4FY21 Reported EBITDA at Rs 244 Crore versus Rs 381 Crore in Q4FY21 Finance costs at Rs 40 Crore vs. Rs 43 Crore in Q4FY21 PAT was at Rs 59 Crore as compared with Rs 173 Crore in Q4FY21 EPS is Rs 3.74 versus Rs 10.86 in Q4FY21 Capital expenditure for the quarter was Rs 87 Crore FY22: Revenue was Rs 6,130 Crore versus Rs 6,099 Crore in FY21 Reported EBITDA at Rs 1,168 Crore versus Rs 1,414 Crore in FY21 Finance costs at Rs 145 Crore vs. Rs 184 Crore in FY21 Average blended interest rate for FY22 improved to 4.56% from 5.07% in FY21 Effective Tax Rate of 34.5% vs. 34.1% in FY21. PAT was at Rs 413 Crore as compared with Rs 574 Crore in FY21 EPS is Rs 26.0 versus Rs 36.05 in FY21 Capital expenditure for the year was Rs 437 Crore Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova Limited said: “In FY 2022, the Company reported stable revenues, despite COVID-19 challenges, due to the diverse range of our businesses. Improved performance in Specialty Pharma business and strong growth in the Contract Research business was offset by lower revenues in the CMO, API and Generics businesses. In Q4FY22, the Company witnessed healthy improvement in operating performance sequentially due to growth in both Pharmaceuticals and Contract Research businesses, however on a YoY basis performance stood lower due to weaker performance in the Pharmaceuticals segment. The Pharmaceuticals segment sequentially witnessed healthy improvement in revenues in all businesses. On a YoY basis, we witnessed growth in Radiopharma and Allergy Immunotherapy businesses and lower performance in CMO business due to tapering of COVID related revenues, lower volumes in Generics business due to import alert and lower volumes in API business. The Contract Research and Development Services business, continued to witness strong growth both on a YoY and sequential basis driven by robust demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our lead program – LSD1/HDAC6 inhibitor has successfully started Phase I/ II trials. Additional IND filings with FDA for pipeline programs are expected to follow in FY23 We are glad to share that the API demerger is progressing as per plan and is expected to be effective from July 2022 onwards with April 1, 2022 as the appointed date. This demerger will enable to create Synergies between CRO & CDMO businesses and help in supporting our customers for their needs from early stage of research to commercialization of active ingredients, and will provide competitive edge to this business. We are also glad to share that the Board has recommended a final dividend of 500% i.e. Rs 5 per equity share of face value of Re 1 each for the FY22 We would like to mention that over the medium term, we have strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.” Result PDF Jubilant Pharmova Ltd - 530019 - Jubilant Pharmova - FY22 Results
In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022 were approved by the Board of Directors of the Company at its meeting held today at 1:15 p.m. and concluded at 4.15 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2022; 2. Audit Reports for Standalone and Consolidated Financial Results; 3. Copies of the Press Release and Presentation. We declare that the Reports of Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2022. Jubilant Pharmova Ltd - 530019 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We wish to inform you that the Hon''ble National Company Law Tribunal, Allahabad Bench ('NCLT') has, by its Order dated May 23, 2022, sanctioned the Scheme of Arrangement under Sections 230-232 and other applicable provisions of the Companies Act, 2013 read with the Companies (Compromises, Arrangements, and Amalgamations) Rules, 2016 between Jubilant Generics Limited (Transferor Company) and Jubilant Pharmova Limited (Transferee Company) and their respective shareholders and creditors. We enclose herewith copy of the order as available on the website of NCLT. The order was available on the website of NCLT on May 24, 2022. We request you to take the same on record. Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that a share certificate has been reported to be lost by the shareholder as per the attachment The Shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue letter of confirmation to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record. Jubilant Pharmova Ltd - 530019 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report dated May 18, 2022 for the financial year 2021-22. We request you to take the same on record.